Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.71 |
| ▸ | CTSK | P43235 | 10/20 | 0.71 |
| ▸ | CTSB | P07858 | 4/20 | 0.71 |
| ▸ | CTSL | P07711 | 2/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | REN | P00797 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556757 | 1.00 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3004474 | 1.00 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5556502 | 0.94 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL11375901 | 0.93 | CTSS (0.63) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16576489 | 0.91 | CTSS (0.60) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16570633 | 0.91 | CTSS (0.60) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18064452 | 0.91 | CTSS (0.60) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16576541 | 0.89 | CTSS (0.61) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16576480 | 0.89 | CTSS (0.66) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6161119 | 0.88 | CTSS (0.70) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018047143-A1 | VISTA SIGNALING PATHWAY INHIBITORY COMPOUNDS USEFUL AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-15 | — | — | WO | disclosed |
| EP-2861581-B9 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2861581-B1 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | CTSS 630/4885CTSK 280/4885CTSB 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.